<DOC>
	<DOC>NCT02415595</DOC>
	<brief_summary>The purpose of this study is to find at least one dose of BMS-955176 that will be safe, effective and tolerable for HIV-1 infected treatment naive adults.</brief_summary>
	<brief_title>Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Men and nonpregnant women, at least 18 years of age Antiretroviral treatmentnaïve; defined as no current or previous exposure to &gt; 1 week of an antiretroviral drug Plasma HIV1 RNA ≥ 1000 copies/mL CD4 Tcell count &gt; 200 cells/mm3 Resistance or partial resistance to any study drug determined by tests at Screening Current or historical genotypic and/or phenotypic drug resistance testing showing certain resistance mutations to EFV, TDF, FTC, Protease Inhibitors Chronic hepatitis B virus (HBV)/ hepatitis C virus (HCV) Blood tests that indicate normal liver function Hemoglobin &lt; 8.0 g/dL, platelets &lt; 50,000 cells/mm3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>